The Neuromuscular Center Jena provides primary and secondary care for patients with motor neurone diseases and neuromuscular diseases. We cover the full range of diagnostics; provide ICU treatment, feeding tube placement and NIV services, regular clinical visits, and coordination of support measures. Our clinical research projects focus on MND biomarker identification in primary patient material and neuroimaging in order to analyse causes and paths of ALS progression. Furthermore, our center is involved in several clinical studies.
| Neuromuscular Center, Clinic of Neurology, Jena University Hospital | |
|---|---|
| Foundation year | 2007 |
| Director | Prof. Dr. med. Matthias Schwab |
| Principal investigator | Dr. Annekathrin Rödiger and Dr. Robert Steinbach |
| Contact information | |
|---|---|
| Address | Am Klinikum 1 |
| Contact | Dr. Beatrice Stubendorff |
| Phone | +49 3641 9 323534 |
| tmz@med.uni-jena.de | |
| Website | Visit the website |
Publications
- Steinbach R, Gaur N, Roediger A, Mayer TE, Witte OW, Prell T, Grosskreutz J. Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model. Hum Brain Mapp. 2021 Feb 15;42(3):737-752. doi: 10.1002/hbm.25258. Epub 2020 Oct 26.
- Steinbach R, Prell T, Gaur N, Roediger A, Gaser C, Mayer TE, Witte OW, Grosskreutz J. Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. Neuroimage Clin. 2021;30:102674. doi: 10.1016/j.nicl.2021.102674. Epub 2021 Apr 15.
- Steinbach R, Prell T, Gaur N, Stubendorff B, Roediger A, Ilse B, Witte OW, Grosskreutz J. Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19 Pandemic: An Application of the D50 Model. J Clin Med. 2020 Sep 5;9(9):2873. doi: 10.3390/jcm9092873.
- Gaur N, Huss E, Prell T, Steinbach R, Guerra J, Srivastava A, Witte OW, Grosskreutz J. Monocyte-Derived Macrophages Contribute to Chitinase Dysregulation in Amyotrophic Lateral Sclerosis: A Pilot Study. Front Neurol. 2021 May 14;12:629332. doi: 10.3389/fneur.2021.629332.
- Dreger M, Steinbach R, Gaur N, Metzner K, Stubendorff B, Witte OW, Grosskreutz J. Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. Front Neurosci. 2021 Apr 6;15:651651. doi: 10.3389/fnins.2021.651651.
Restricted information
| Serving population | |
|---|---|
| Serving population | Unknown |
| Patient resources | |
|---|---|
| Population based register | No |
| Clinic based register | Yes |
| Geographically matched controls | Yes |
| Number of muscle samples | 50 |
| Number of skin samples | 75 |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA Bank | 200 | 150 | 100 |
| Serum Bank | 350 | 100 | 350 |
| RNA Bank | 125 | 35 | 10 |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | Yes |
| Neuro psychology | Yes |
| Neuro pathology | Yes |
| Genomics | No |
| Transcriptomics | No |
| Metabolomics | No |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| Courage-ALS (Cytokinetics) | A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis | |
| MT-1186-A02 (Mitsubishi Tanabe Pharma Development America, Inc.) | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | |
| Phoenix (Amylyx Pharmaceuticals Inc.) | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment | |
| MERIDIAN (Apellis Pharmaceuticals, Inc.) | Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) |
Clinical Trials - Investigator initiated
| Name | Type | Patients |
|---|---|---|
| SMArtCARE (University of Freiburg) | Follow-up observation and therapy evaluation in spinal muscular atrophy | |
| NFL study (Charité Berlin) | Research program on the biomarker neurofilament light chain in ALS | |
| ID-ALS (Charité Berlin) | Research program for the identification of genetic changes in ALS | |
| TUDCA-ALS (Humanitas Mirasole S.p.A.) | Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis |